Lynk Pharmaceuticals has announced promising topline results from its Phase III trial of zemprocitinib, aimed at treating moderate-to-severe atopic dermatitis, demonstrating significant efficacy and safety.

Lynk Pharmaceuticals has announced the successful completion of patient enrollment in a Phase III clinical trial evaluating its innovative drug, Zemprocitinib, for ankylosing spondylitis.

HANGZHOU, China and SHANGHAI and BOSTON, July 14, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced that patient enrollment was completed on July 9...

Lynk Pharmaceuticals has reported another phase 3 win in China for its next-gen JAK inhibitor, this time hitting skin clearance goals among patients with eczema. The Hangzhou, China-based biotech assessed two oral doses of zemprocitinib against placebo in the late-stage study of 356 patients with moderate to severe atopic dermatitis (AD). When it came to the proportion of patients who experienced a 75% or greater improvement in their eczema severity score, the 12-mg zemprocitinib cohort outperformed the placebo group by 38.1%.

Selon les résultats d'un essai clinique de phase III, le zemprocitinib, un inhibiteur de JAK1 de nouvelle génération, pourrait permettre de maîtriser la polyarthrite rhumatoïde qui ne répond pas ...

HANGZHOU, China, SHANGHAI and BOSTON, Jan. 12, 2026 /PRNewswire/ — Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as “Lynk Pharmaceuticals”), a clinical stage innovative drug development company focused on developing innovative therapies for immune and inflammatory diseases, today announced positive topline results from its Phase III clinical trial evaluating zemprocitinib (LNK01001) in patients with moderate to […]

Lynk Pharmaceuticals has reported another phase 3 win in China for its next-gen JAK inhibitor, this time hitting skin clearance goals among patients with eczema. The Hangzhou, China-based biotech assessed two oral doses of zemprocitinib against placebo in the late-stage study of 356 patients with moderate to severe atopic dermatitis (AD). When it came to the proportion of patients who experienced a 75% or greater improvement in their eczema severity score, the 12-mg zemprocitinib cohort outperformed the placebo group by 38.1%.

Lynk’s zemprocitinib commercial partner, Simcere, will now continue the JAK inhibitor’s development across China in RA.

Lynk Pharmaceuticals announces positive topline data from Phase III trials of Zemprocitinib, showcasing significant efficacy in patients with rheumatoid arthritis.

SHANGHAI, HANGZHOU, China and BOSTON, April 10, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on therapies for immune and inflammatory diseases, today announced that the New Drug Application (NDA)...

SHANGHAI, HANGZHOU, China and BOSTON, March 2, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on therapies for immune and inflammatory diseases, today announced positive topline results from its...